Alexander N. Shoushtari, MD

In this final segment, our panel looks ahead at where the field is going and what the next wave of advances could mean for patients who do not yet have good options.

In this segment, our panel makes the case for universal HLA-A*02:01 testing in every uveal melanoma patient and gives you the practical tools to make it happen in your practice today.

In this segment, our panel gets into the specifics of how academic and community oncologists can work together to ensure patients on tebentafusp stay on therapy and receive the right guidance throughout their treatment.

In this segment, our panel addresses one of the most important and underappreciated problems in uveal melanoma care: the gap between patients who are eligible for effective therapy and patients who actually receive it.

In this segment, our panel addresses the practical realities of administering tebentafusp week after week, including how leading centers have built workflows that allow patients to transition from academic induction to community-based ongoing dosing without interrupting treatment continuity.

In this segment, our panel takes a closer look at the Phase 3 trial data supporting tebentafusp, exploring what the overall survival benefit means in the context of modest response rates and limited progression-free survival, and why this trial changed how the field thinks about measuring success in uveal melanoma.

In this segment, our panel prepares you for what to expect when you start a patient on tebentafusp, covering the toxicity profile in practical detail and explaining why the first few doses look very different from what comes later.

In this segment, our panel explains the mechanism of bispecific T-cell engager therapy and why it works differently from every other approach that has been tried in uveal melanoma.

In this segment, our panel puts the current treatment landscape for metastatic uveal melanoma into historical context, walking through the long series of agents that failed to move the needle before the recent shift in what is achievable for these patients.

In this segment, our panel goes deeper into the molecular workup for uveal melanoma, covering the prognostic significance of BAP1, SF3B1, and EIF1AX mutations alongside gene expression profiling, and explaining how PRAME is emerging as both a prognostic marker and a potential therapeutic target.

In this segment, our panel walks through the initial workup for a patient newly diagnosed with uveal melanoma, with a focus on how gene expression profiling and PRAME status are used to stratify patients by metastatic risk.

In this segment, our panel establishes why uveal melanoma is a fundamentally different disease from cutaneous melanoma and why that distinction matters for every treatment decision that follows.

Alexander N. Shoushtari, discusses the rationale for the ​phase 3 CheckMate-067 trial in advanced melanoma.

Alexander N. Shoushtari, MD, discusses the design of the ​phase 3 CheckMate-067 trial in advanced melanoma. 

Alexander N. Shoushtari, MD, discusses the role of nivolumab and ipilimumab in mucosal melanoma. 

Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.